- 作 者: "List, Benjamin"
-
The Silicon–Hydrogen Exchange Reaction: Catalytic Kinetic Resolution of 2-Substituted Cyclic KetonesSynlett (IF 2.17) Pub Date : 2021-10-15 ,DOI:10.1055/a-1670-5829List, Benjamin, Zhou, Hui, Zhang, Pinglu
We have recently reported the strong and confined, chiral acid-catalyzed asymmetric “silicon−hydrogen exchange reaction”. One aspect of this transformation is that it enables access to enantiopure enol silanes in a tautomerizing σ-bond metathesis, via deprotosilylation of ketones with allyl silanes as the silicon source. However, until today, this reaction has not been applied to racemic, 2-substituted
...
-
Highly efficient cold-white light emission in a [Au2CuCl2(P∩N)2]PF6 type salt†Dalton Transactions (IF 4.569) Pub Date : 2017-02-09 ,DOI:10.1039/c7dt00180kElnaz Hobbollahi,Manuela List,Benjamin Hupp,Fabian Mohr,Raphael J. F. Berger,Andreas Steffen,Uwe Monkowius
In the trinuclear, heterometallic cluster compound [Au2CuCl2(P∩N)2]PF6 metallophilic interactions give rise to very efficient cold-white light emission as a result of at least two thermally non-equilibrated emissive triplet states (one of mainly Cu → py and the other of Au → py character, respectively) with exceptional spin–orbit coupling and short emission lifetimes, which are competitive to PtII-
...
-
Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic SyndromesBlood (IF 25.476) Pub Date : 2010-11-19 ,DOI:10.1182/blood.v116.21.3995.3995Tea Reljic, Neera Bhansali, Rami S. Komrokji, Karen Lin, Alan F. List, Benjamin Djulbegovic, David A. Fenstermacher, Jeffrey E. Lancet, Branko Miladinovic, Ambuj KumarAbstract 3995 Background: Azacitidine (5-AzaC) and decitabine (DAC) are two hypomethylating agents commonly used in treatment of Myelodysplastic Syndromes (MDS). The comparative effectiveness of 5-AzaC versus DAC is not known. Both agents have been tested against supportive care in controlled settings, but not head-to-head. The most comprehensive assessment of the efficacy of 5-AzaC versus DAC was ...
-
-
Different Molecular Mechanisms of Force Enhancement by Myosin Head Domain Mutations R723G and R453CBiophysical Journal (IF 3.699) Pub Date : 2009-02-01 ,DOI:10.1016/j.bpj.2008.12.2562Dejan List, Benjamin Seebohm, Faramarz Matinmehr, William J. McKenna, Antonio Francino, Francisco Navarro-Lopez, Bernhard Brenner, Theresia KraftThe myosin head transforms chemical energy from ATP hydrolysis into mechanical work to generate isometric force or to drive muscle shortening. During the power stroke, small changes in the catalytic ATPase site of the actin-bound myosin head are coupled to tilting of the light-chain binding domain relative to the catalytic domain. In this mechanism distortion of an elastic element within the actomyosin ...
-
Direct catalytic asymmetric alpha-amination of aldehydes.Journal of the American Chemical Society (IF 16.383) Pub Date : 2002 May 2 ,DOI:List, BenjaminThe first direct catalytic asymmetric alpha-amination of aldehydes is described herein. alpha-Unbranched aldehydes react in this novel proline-catalyzed reaction with dialkyl azodicarboxylates to give alpha-amino aldehydes in excellent yields and enantioselectivities. ...
-
The proline-catalyzed direct asymmetric three-component Mannich reaction: scope, optimization, and application to the highly enantioselective synthesis of 1,2-amino alcohols.Journal of the American Chemical Society (IF 16.383) Pub Date : 2002 Feb 6 ,DOI:List, Benjamin, Pojarliev, Peter, Biller, William T, Martin, Harry JWe have developed proline-catalyzed direct asymmetric three-component Mannich reactions of ketones, aldehydes, and amines. Several of the studied reactions provide beta-amino carbonyl compounds (Mannich products) in excellent enantio-, diastereo-, regio-, and chemoselectivities. The scope of each of the three components and the influence of the catalyst structure on the reaction are described. Reaction ...
-
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.Leukemia (IF 12.883) Pub Date : 2018-Jul-0 ,DOI:10.1038/s41375-018-0029-9Alan List,Benjamin L. Ebert,Pierre FenauxThere are few instances in oncology where reciprocal clinical and laboratory translation studies have accelerated the understanding of disease biology and treatment more so than the decade following the Food and Drug Administration (FDA) approval of lenalidomide (RevlimidTM; Celgene Corporation, Summit, NJ, USA) for the treatment of patients with myelodysplastic syndrome (MDS) and chromosome 5q deletion ...
广告：喜“文”乐“荐”|邀请好友使用Taylor & Francis Editing Services编辑润色服务，共享专属优惠！推荐人数无限制！
高级搜索
我的搜索条件
京公网安备 11010802027423号